NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5 November 2009 A study has found evidence of selective outcome reporting in industry-sponsored reports of randomised trials of off-label use of gabapentin. For eight of the twelve reported […]
Category Archives: Evidence informed decision-making (EIDM)
NPC Archive Item: Use of NICE appraised medicines in the NHS
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 September 2009 A report from the NHS Information Centre assessed the variation in the use of 26 medicines positively approved by NICE in 13 technology appraisals. In 7 […]
NPC Archive Item: Beware citations bias
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18th August 2009 A recent study identified how citations made in the biomedical literature may selectively report work that does not represent the spectrum of available evidence, and can […]
NPC Archive Item: Even limited exposure to pharmaceutical promotion may influence subconscious attitudes to marketed medicines
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18th August 2009 A randomised controlled experiment in US medical students suggests that subtle exposure to small, inexpensive pharmaceutical promotional items influences implicit (i.e. subconscious) attitudes towards branded medicines. […]
NPC Archive Item: Inadequate sample size calculation and reporting in clinical trials: what does it mean for me?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 12th August 2009 A review of publications of randomised controlled trials found that only a third adequately described the sample size calculations. This is needed to base the statistical […]
NPC Archive Item: Press releases may not report research in an impartial manner
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 16th June 2009 A review has found that academic centre press releases often overstate the importance of the findings of their own research, while underemphasising cautions that limit the […]
NPC Archive Item: RECORD study confirms heart failure and fracture risks of rosiglitazone: uncertainties remain over other CV risks
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15th June 2009 The authors of this non-inferiority study claim non-inferiority of dual therapy with rosiglitazone plus metformin or a sulfonylurea compared to dual therapy with metformin plus a […]
NPC Archive Item: NPC rapid reviews now indicate the level of evidence
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 1st June 2009 From 1st June 2009 MeReC Rapid Reviews will indicate the level of evidence of the clinical study we report using the SORT criteria. We hope that […]
NPC Archive Item: Don’t miss out on news you want to hear
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th February 2009 Don’t miss out on news you want to hear Make sure you are signed up to NPC Email updates — the free email alerting system that […]
NPC Archive Item: Publication bias identified for drugs receiving U.S licensing approval
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. North American authors of an observational study have found evidence of incomplete and selective publication of clinical trials that supported successful licence applications to the FDA during the time […]